Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

NCT06814158 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamour Cell Cancer

Interventions

DRUG: Ivonescimab Combined With Chemotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital